	trifluoro-1-hydroxyethyl)quinolin-2(1H)-one (Isomer-2);
104.	6-(3,5-dimethylisoxazol-4-yl)-7-methoxy-1-(pyridin-2-ylmethyl)-3-(2,2,2-trifluoro-1,1-dihydroxyethyl)quinolin-2(1H)-one;
105.	1-(4-chlorophenethyl)-6-(3,5-dimethylisoxazol-4-yl)-7-methoxy-3-methyl-2-oxo-1,2-dihydroquinoline-4-carbonitrile; and
106.	2-(1-(4-chlorophenethyl)-6-(3,5-dimethylisoxazol-4-yl)-7-methoxy-2-oxo-1,2-dihydroquinolin-3-yl)acetonitrile,

or a pharmaceutically acceptable salt or a pharmaceutically acceptable stereoisomer thereof.

13. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of formula (I) according to any of claims 1 to 12, or a pharmaceutically acceptable salt or a pharmaceutically acceptable stereoisomer thereof, in admixture with atleast one pharmaceutically acceptable carrier or excipient including mixtures thereof in all ratios, for use as a medicament.

14. A pharmaceutical combination comprising a therapeutically effective amount of at least one compound of formula (I) according to any of claims 1 to 12, or a pharmaceutically acceptable salt or a pharmaceutically acceptable stereoisomer thereof, and at least one therapeutically further active ingredient.

15. A compound according to any of the claims 1 to 12, or a pharmaceutically acceptable salt or a pharmaceutically acceptable stereoisomer thereof, for use in therapy.

16. Use of a compound according to any of claims 1 to 12, in manufacture of a medicament for use in treatment of diseases associated with bromodomain in animals including humans, wherein the diseases associated with bromodomain comprise autoimmune, inflammatory or cancer.